Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 91

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 91
---
 take actions to resolve in accordance with the best interests of Enfusion and Enfusion Stockholders in their capacity as such, any developments or circumstances that would reasonably be expected to pose an actual or
potential conflict of interest affecting any director, officer, agent, employee or stockholder of Enfusion relative to a potential transaction or other alternative, a potential counterparty with respect to a potential transaction or other
alternative, and (i) engage the Special Committee’s own financial and legal advisors in connection with the foregoing. The Enfusion Board further resolved that the Enfusion Board would not approve a strategic transaction without a prior
favorable recommendation of such transaction by the Special Committee.

On August 16, 2024, the Special Committee held its
inaugural meeting with representatives of Goodwin and the General Counsel and Assistant General Counsel of Enfusion in attendance. The Special Committee interviewed law firms, including Dechert LLP (“”), to potentially serve
as outside counsel to the Special Committee.

On August 23, 2024, the Special Committee held a meeting with the General Counsel
and Assistant General Counsel of Enfusion in attendance. The Special Committee determined to select Dechert to serve as outside

59

counsel to the Special Committee based on Dechert’s expertise and other qualifications, including knowledge of the industry in which Enfusion operates and experience advising technology
companies and special committees in connection with the review and implementation of strategic alternatives, including strategic transactions.

On August 27, 2024, FTV confirmed that, at that time, FTV did not have an interest in acquiring Enfusion or have an intention to
proactively seek a rollover of their shares in a potential transaction and that FTV did not presently regard a rollover to be a condition to supporting a transaction and that FTV would promptly inform Goodwin if any of these declarations were to
change. FTV also confirmed that, unless approved in advance by the Special Committee, FTV would not enter into discussions or negotiations with any potential buyer, nor with ICONIQ or Mr. Movchan, regarding rollover, participating in any buyer
group or the treatment otherwise of their equity interests in Enfusion in a potential transaction, or the treatment of the TRA in a potential transaction.

On August 30, 2024, the Special Committee held a meeting with representatives of Dechert in attendance. By invitation of the Special
Committee, the other members of the Enfusion Board, certain members of Enfusion management and representatives of Goodwin were